CelLBxHealth (FRA:DWV) Total Inventories: €1.48 Mil (As of Dec. 2025)


What is CelLBxHealth Total Inventories?

CelLBxHealth FRA:DWV -8.11% Total Inventories is €1.48 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

CelLBxHealth's total inventories for the quarter that ended in Dec. 2025 was €1.48 Mil. CelLBxHealth's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was €1.67 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. CelLBxHealth's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was €0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. CelLBxHealth's Days Inventory for the six months ended in Dec. 2025 was 1,407.62.

Inventory Turnover measures how fast the company turns over its inventory within a year. CelLBxHealth's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.13.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CelLBxHealth's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 2.63.

CelLBxHealth  (FRA:DWV) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

CelLBxHealth's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(8.402+0.75 * 0.127+0.5 * 1.482-6.16
-0-0)/1946.960
=0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CelLBxHealth's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=1.666/0.216*365 / 2
=1,407.62

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

CelLBxHealth's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=0.216 / 1.666
=0.13

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CelLBxHealth's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=1.666 / 0.634
=2.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

CelLBxHealth Total Inventories Related Terms

CelLBxHealth Total Inventories Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Total Inventories Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.06 2.37 1.95 1.91 1.48

CelLBxHealth Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 2.08 1.91 1.85 1.48

CelLBxHealth Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of €1.48 Mil mean?
CelLBxHealth (FRA:DWV) has a Total Inventories of €1.48 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for CelLBxHealth and its competitors.
Is CelLBxHealth's Total Inventories too high?
CelLBxHealth's current Total Inventories is €1.48 Mil.
How does CelLBxHealth's Total Inventories compare to TMO and DHR?
CelLBxHealth's Total Inventories of €1.48 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for CelLBxHealth and its competitors. CelLBxHealth's current Total Inventories is €1.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (FRA:DWV) has a current Total Inventories of €1.48 Mil. The current Total Inventories is €1.48 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Total Inventories is €1.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.